Genmab A/S Dkk (GNMSF) 80.5000 $GNMSF
HuMax-TF-ADC and Daratumumab Data to Be Presented at 2015 ASCO Annual Meeting
GlobeNewswire - Wed May 13, 4:10PM CDT
Company Announcement
GEN: 7.04 (+0.12)
Genmab's (GNMSF) CEO Jan van de Winkel on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue May 12, 7:17PM CDT
Genmab Announces Financial Results for the First Quarter of 2015
GlobeNewswire - Tue May 12, 10:11AM CDT
Interim Report First Quarter 2015
First Quarter 2015 Net Sales Figures for Arzerra(r) (Ofatumumab)
GlobeNewswire - Wed May 06, 6:14AM CDT
-- Worldwide net sales of Arzerrain Q1 2015 totaled GBP 11.1 million
GEN: 7.04 (+0.12)
Genmab Announces Phase III Study of Arzerra(r) Met Primary Endpoint of Improved Progression-Free Survival in Patients with Relapsed CLL
GlobeNewswire - Mon Apr 27, 9:26AM CDT
Company Announcement
GEN: 7.04 (+0.12)
Genmab Achieves USD 10 Million Milestone in Daratumumab Collaboration with Janssen
GlobeNewswire - Thu Apr 16, 8:46AM CDT
Company Announcement
GEN: 7.04 (+0.12)
Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to two Board Members and Grant of Warrants to Employees in Genmab
GlobeNewswire - Thu Mar 26, 1:10PM CDT
Following Genmab A/S' (Copenhagen:GEN) Annual General Meeting held on March 26, 2015, the Company's Board of Directors met to constitute itself. Mats Pettersson was appointed Chairman and Dr. Anders Gersel Pedersen was appointed Deputy Chairman. It was decided to grant 5,400 restricted stock units to the two new members of the Board of Directors and to issue 22,050 warrants to employees of the Company and the Company's subsidiaries.
GEN: 7.04 (+0.12)
Genmab Acquires Antibody Assets from iDD Biotech
GlobeNewswire - Wed Mar 18, 9:14AM CDT
Company Announcement
GEN: 7.04 (+0.12)
Genmab Retains Partial Rights for HuMax-TAC-ADC - Will Not Exercise Co-development Right
GlobeNewswire - Mon Mar 16, 5:36AM CDT
Company Announcement
GEN: 7.04 (+0.12)
Capital Increase in Genmab as a Result of Employee Warrant Exercise and Projection of Improved Cash Position at the End of 2015
GlobeNewswire - Wed Mar 11, 12:16PM CDT
Genmab A/S (Copenhagen:GEN) will increase its share capital by 1,166,245 shares as a consequence of the exercise of employee warrants.
GEN: 7.04 (+0.12)
Esophageal Cancer Therapeutics Pipeline Review 2015 - 40 Companies & 57 Drug Profiles
M2 - Wed Mar 11, 7:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2mqnm8/esophageal_cancer) has announced the addition of the "Esophageal Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Esophageal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Esophageal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Advantagene, Inc. - Advaxis, Inc. - Amgen Inc. - ArQule, Inc. - Aslan Pharmaceuticals Pte. Ltd. - AstraZeneca PLC - AVEO Pharmaceuticals, Inc. - Bellicum Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celgene Corporation - Cellectar Biosciences, Inc. - Cerulean Pharma, Inc. - Daiichi Sankyo Company, Limited - Genmab A/S - GlaxoSmithKline plc - Glycotope GmbH - Hutchison MediPharma Limited - ImmunoFrontier, Inc. - ImmunoGen, Inc. - Immunomedics, Inc. - Karyopharm Therapeutics, Inc. - Mebiopharm Co., Ltd. - Meiji Seika Pharma Co., Ltd. - Merrimack Pharmaceuticals, Inc. - Novartis AG - Omeros Corporation - Omnitura Therapeutics Inc. - Oncolys BioPharma Inc. - Ono Pharmaceutical Co., Ltd. For more information visit http://www.researchandmarkets.com/research/2m...eal_cancer
CLRB: 2.80 (+0.06), IMMU: 4.22 (+0.10), ADXS: 20.90 (+0.82), CERU: 6.37 (+0.22), IMGN: 8.67 (+0.08), ARQL: 1.85 (-0.02), AMGN: 163.44 (+1.08), GSK: 44.66 (-0.11), BMY: 68.00 (+0.36), OMER: 20.99 (+0.11), MACK: 13.07 (+0.41), BLCM: 22.18 (-0.84), AZN: 68.74 (-0.55), AVEO: 1.24 (+0.05), NVS: 104.06 (+0.31), KPTI: 27.02 (+2.21), CELGZ: 2.60 (unch)
Genmab's (GNMSF) CEO Jan Winkel on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Mar 02, 5:35PM CST
Genmab 2014 Annual Report
GlobeNewswire - Mon Mar 02, 10:07AM CST
Genmab A/S (OMX: GEN) announced today its Annual Report for 2014. Below is a summary from the report of business progress and financial performance for the year, and financial outlook for 2015. The full report is attached as a PDF file and can be found on the investor section of the company's website, www.genmab.com.
GEN: 7.04 (+0.12)
Genmab Announces That Agreement to Transfer Ofatumumab Collaboration to Novartis is Now Effective
GlobeNewswire - Mon Mar 02, 12:48AM CST
Company Announcement
GEN: 7.04 (+0.12), NVS: 104.06 (+0.31)
Genmab Enters Commercial DuoBody Technology Agreement with BioNovion in the Field of Immuno-Oncology
GlobeNewswire - Thu Feb 19, 9:14AM CST
Company Announcement
GEN: 7.04 (+0.12)
Major Shareholder Announcement
GlobeNewswire - Wed Feb 04, 4:58PM CST
Company Announcement
GEN: 7.04 (+0.12)
Fourth Quarter and Full Year 2014 Net Sales Figures for Arzerra (ofatumumab)
GlobeNewswire - Wed Feb 04, 6:05AM CST
Company Announcement
GEN: 7.04 (+0.12)
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/2n69ld/relapsing) has announced the addition of the "Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects Scope - The report provides a snapshot of the global therapeutic landscape of Relapsing Remitting Multiple Sclerosis (RRMS) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Relapsing Remitting Multiple Sclerosis (RRMS) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Relapsing Remitting Multiple Sclerosis (RRMS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Relapsing Remitting Multiple Sclerosis (RRMS) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - F. Hoffmann-La Roche Ltd. - Sanofi - GlaxoSmithKline plc - MedImmune, LLC - XenoPort, Inc. - Novartis AG - Actelion Ltd - Mitsubishi Tanabe Pharma Corporation - Octapharma AG - Teva Pharmaceutical Industries Limited - Genmab A/S - Merck KGaA - Antisense Therapeutics Limited - Opexa Therapeutics - Trophos SA - Allozyne - Amarna Therapeutics - Synthetic Biologics - Cognosci - RedHill Biopharm - Nuron Biotech - Neurotec Pharma SL - BIOCAD - AbbVie Inc. For more information visit http://www.researchandmarkets.com/research/2n69ld/relapsing
GSK: 44.66 (-0.11), XNPT: 6.17 (+0.23), OPXA: 0.37 (-0.01), SYN: 1.94 (+0.07), ABBV: 65.61 (-0.38), TEVA: 60.19 (-0.04), NVS: 104.06 (+0.31)
How Genmab (GNMSF) Stock Stands Out in a Strong Industry - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 19, 7:30AM CST
Genmab is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/dsgsvz/chronic) has announced the addition of the "Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Lymphocytic Leukemia (CLL) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - Amgen Inc. - Sanofi - Eli Lilly and Company - Viralytics Ltd. - Genentech, Inc. - MedImmune, LLC - Gilead Sciences, Inc. - Daiichi Sankyo Company, Limited - Emergent BioSolutions Inc. - Lentigen Corporation - Amorfix Life Sciences Ltd. - Piramal Enterprises Limited - Celltrion, Inc. - Astellas Pharma Inc. - BioMarin Pharmaceutical Inc. - Richter Gedeon Nyrt. - Astex Pharmaceuticals, Inc. - Genmab A/S - Cyclacel Pharmaceuticals Inc. - Celgene Corporation - Onyx Pharmaceuticals, Inc. - Bayer AG - Incyte Corporation - Merck KGaA - 4SC AG - Celldex Therapeutics, Inc. - Immunomedics, Inc. - TG Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/dsgsvz/chronic
BMRN: 126.02 (+3.24), CLDX: 26.26 (+0.45), CYCC: 0.77 (-0.04), IMMU: 4.22 (+0.10), EBS: 30.91 (+0.19), INCY: 107.65 (+0.79), TGTX: 16.22 (unch), AMGN: 163.44 (+1.08), LLY: 72.94 (+0.04), BMY: 68.00 (+0.36), GILD: 111.00 (+1.70), CELGZ: 2.60 (unch)
HuMax-TF-ADC and Daratumumab Data to Be Presented at 2015 ASCO Annual Meeting
GlobeNewswire - Wed May 13, 4:10PM CDT
Company Announcement
GEN: 7.04 (+0.12)
Genmab's (GNMSF) CEO Jan van de Winkel on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue May 12, 7:17PM CDT
Genmab Announces Financial Results for the First Quarter of 2015
GlobeNewswire - Tue May 12, 10:11AM CDT
Interim Report First Quarter 2015
First Quarter 2015 Net Sales Figures for Arzerra(r) (Ofatumumab)
GlobeNewswire - Wed May 06, 6:14AM CDT
-- Worldwide net sales of Arzerrain Q1 2015 totaled GBP 11.1 million
GEN: 7.04 (+0.12)
Genmab Announces Phase III Study of Arzerra(r) Met Primary Endpoint of Improved Progression-Free Survival in Patients with Relapsed CLL
GlobeNewswire - Mon Apr 27, 9:26AM CDT
Company Announcement
GEN: 7.04 (+0.12)
Genmab Achieves USD 10 Million Milestone in Daratumumab Collaboration with Janssen
GlobeNewswire - Thu Apr 16, 8:46AM CDT
Company Announcement
GEN: 7.04 (+0.12)
Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to two Board Members and Grant of Warrants to Employees in Genmab
GlobeNewswire - Thu Mar 26, 1:10PM CDT
Following Genmab A/S' (Copenhagen:GEN) Annual General Meeting held on March 26, 2015, the Company's Board of Directors met to constitute itself. Mats Pettersson was appointed Chairman and Dr. Anders Gersel Pedersen was appointed Deputy Chairman. It was decided to grant 5,400 restricted stock units to the two new members of the Board of Directors and to issue 22,050 warrants to employees of the Company and the Company's subsidiaries.
GEN: 7.04 (+0.12)
Genmab Acquires Antibody Assets from iDD Biotech
GlobeNewswire - Wed Mar 18, 9:14AM CDT
Company Announcement
GEN: 7.04 (+0.12)
Genmab Retains Partial Rights for HuMax-TAC-ADC - Will Not Exercise Co-development Right
GlobeNewswire - Mon Mar 16, 5:36AM CDT
Company Announcement
GEN: 7.04 (+0.12)
Capital Increase in Genmab as a Result of Employee Warrant Exercise and Projection of Improved Cash Position at the End of 2015
GlobeNewswire - Wed Mar 11, 12:16PM CDT
Genmab A/S (Copenhagen:GEN) will increase its share capital by 1,166,245 shares as a consequence of the exercise of employee warrants.
GEN: 7.04 (+0.12)
Esophageal Cancer Therapeutics Pipeline Review 2015 - 40 Companies & 57 Drug Profiles
M2 - Wed Mar 11, 7:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2mqnm8/esophageal_cancer) has announced the addition of the "Esophageal Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Esophageal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Esophageal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Advantagene, Inc. - Advaxis, Inc. - Amgen Inc. - ArQule, Inc. - Aslan Pharmaceuticals Pte. Ltd. - AstraZeneca PLC - AVEO Pharmaceuticals, Inc. - Bellicum Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celgene Corporation - Cellectar Biosciences, Inc. - Cerulean Pharma, Inc. - Daiichi Sankyo Company, Limited - Genmab A/S - GlaxoSmithKline plc - Glycotope GmbH - Hutchison MediPharma Limited - ImmunoFrontier, Inc. - ImmunoGen, Inc. - Immunomedics, Inc. - Karyopharm Therapeutics, Inc. - Mebiopharm Co., Ltd. - Meiji Seika Pharma Co., Ltd. - Merrimack Pharmaceuticals, Inc. - Novartis AG - Omeros Corporation - Omnitura Therapeutics Inc. - Oncolys BioPharma Inc. - Ono Pharmaceutical Co., Ltd. For more information visit http://www.researchandmarkets.com/research/2m...eal_cancer
CLRB: 2.80 (+0.06), IMMU: 4.22 (+0.10), ADXS: 20.90 (+0.82), CERU: 6.37 (+0.22), IMGN: 8.67 (+0.08), ARQL: 1.85 (-0.02), AMGN: 163.44 (+1.08), GSK: 44.66 (-0.11), BMY: 68.00 (+0.36), OMER: 20.99 (+0.11), MACK: 13.07 (+0.41), BLCM: 22.18 (-0.84), AZN: 68.74 (-0.55), AVEO: 1.24 (+0.05), NVS: 104.06 (+0.31), KPTI: 27.02 (+2.21), CELGZ: 2.60 (unch)
Genmab's (GNMSF) CEO Jan Winkel on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Mar 02, 5:35PM CST
Genmab 2014 Annual Report
GlobeNewswire - Mon Mar 02, 10:07AM CST
Genmab A/S (OMX: GEN) announced today its Annual Report for 2014. Below is a summary from the report of business progress and financial performance for the year, and financial outlook for 2015. The full report is attached as a PDF file and can be found on the investor section of the company's website, www.genmab.com.
GEN: 7.04 (+0.12)
Genmab Announces That Agreement to Transfer Ofatumumab Collaboration to Novartis is Now Effective
GlobeNewswire - Mon Mar 02, 12:48AM CST
Company Announcement
GEN: 7.04 (+0.12), NVS: 104.06 (+0.31)
Genmab Enters Commercial DuoBody Technology Agreement with BioNovion in the Field of Immuno-Oncology
GlobeNewswire - Thu Feb 19, 9:14AM CST
Company Announcement
GEN: 7.04 (+0.12)
Major Shareholder Announcement
GlobeNewswire - Wed Feb 04, 4:58PM CST
Company Announcement
GEN: 7.04 (+0.12)
Fourth Quarter and Full Year 2014 Net Sales Figures for Arzerra (ofatumumab)
GlobeNewswire - Wed Feb 04, 6:05AM CST
Company Announcement
GEN: 7.04 (+0.12)
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/2n69ld/relapsing) has announced the addition of the "Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects Scope - The report provides a snapshot of the global therapeutic landscape of Relapsing Remitting Multiple Sclerosis (RRMS) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Relapsing Remitting Multiple Sclerosis (RRMS) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Relapsing Remitting Multiple Sclerosis (RRMS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Relapsing Remitting Multiple Sclerosis (RRMS) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - F. Hoffmann-La Roche Ltd. - Sanofi - GlaxoSmithKline plc - MedImmune, LLC - XenoPort, Inc. - Novartis AG - Actelion Ltd - Mitsubishi Tanabe Pharma Corporation - Octapharma AG - Teva Pharmaceutical Industries Limited - Genmab A/S - Merck KGaA - Antisense Therapeutics Limited - Opexa Therapeutics - Trophos SA - Allozyne - Amarna Therapeutics - Synthetic Biologics - Cognosci - RedHill Biopharm - Nuron Biotech - Neurotec Pharma SL - BIOCAD - AbbVie Inc. For more information visit http://www.researchandmarkets.com/research/2n69ld/relapsing
GSK: 44.66 (-0.11), XNPT: 6.17 (+0.23), OPXA: 0.37 (-0.01), SYN: 1.94 (+0.07), ABBV: 65.61 (-0.38), TEVA: 60.19 (-0.04), NVS: 104.06 (+0.31)
How Genmab (GNMSF) Stock Stands Out in a Strong Industry - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 19, 7:30AM CST
Genmab is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/dsgsvz/chronic) has announced the addition of the "Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Lymphocytic Leukemia (CLL) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - Amgen Inc. - Sanofi - Eli Lilly and Company - Viralytics Ltd. - Genentech, Inc. - MedImmune, LLC - Gilead Sciences, Inc. - Daiichi Sankyo Company, Limited - Emergent BioSolutions Inc. - Lentigen Corporation - Amorfix Life Sciences Ltd. - Piramal Enterprises Limited - Celltrion, Inc. - Astellas Pharma Inc. - BioMarin Pharmaceutical Inc. - Richter Gedeon Nyrt. - Astex Pharmaceuticals, Inc. - Genmab A/S - Cyclacel Pharmaceuticals Inc. - Celgene Corporation - Onyx Pharmaceuticals, Inc. - Bayer AG - Incyte Corporation - Merck KGaA - 4SC AG - Celldex Therapeutics, Inc. - Immunomedics, Inc. - TG Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/dsgsvz/chronic
BMRN: 126.02 (+3.24), CLDX: 26.26 (+0.45), CYCC: 0.77 (-0.04), IMMU: 4.22 (+0.10), EBS: 30.91 (+0.19), INCY: 107.65 (+0.79), TGTX: 16.22 (unch), AMGN: 163.44 (+1.08), LLY: 72.94 (+0.04), BMY: 68.00 (+0.36), GILD: 111.00 (+1.70), CELGZ: 2.60 (unch)
